Akebia Therapeutics

AKBA · Nasdaq · United States

Share price · AKBA

$0.41-0.44 (-52.00%) 3M

close as of 2026-11-18 · 24h delayed · vol 7.1M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when AKBA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 9 Nov 2026+32.8%
  2. 5 Nov 2026-38.8%
  3. 28 Oct 2026+15.8%
  4. 26 Oct 2026+13.6%
  5. 20 Oct 2026-9.1%

    Nothing announced by AKBA that day or the session before.

  6. 6 Aug 2026-26.0%
  7. 20 May 2026+12.8%

    Nothing announced by AKBA that day or the session before.

  8. 19 May 2026-11.4%

    Nothing announced by AKBA that day or the session before.

  9. 7 May 2026-20.3%
  10. 16 Apr 2026-12.9%

    Nothing announced by AKBA that day or the session before.

Share of unusual movement by asset

For each asset, the share of AKBA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Vadadustat (Vafseo)
events and moves
1822%
Praliciguat
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—37%
Sessions with no dated event—40%

Assets

(3 total)
3Total Assets
1Approved
0Phase 3 / Filed
2Phase 1–2 / Early
4Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Vadadustat(Vafseo)
Approved
HIF prolyl hydroxylase (HIF-PH1/2/3)Small molecule
Chronic Kidney Disease
Phase 2
C3d / Factor HProtein / enzyme therapeutic
IgA NephropathyLupus Nephritis
Phase 2
Soluble guanylate cyclaseSmall molecule
Chronic Kidney DiseaseFocal Segmental Glomerulosclerosis

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
PraliciguatPhase 2Focal Segmental Glomerulosclerosis
Est. primary completion 2027-06 · NCT07268638 · CT.gov ↗
What to watch
2028 (1)
February 2028 (1)
Ebribafusp alfaPhase 2IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy
Est. primary completion 2028-02 · NCT06419205 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

5 November 2026Topline resultVadadustatVOCAL meets its non-inferiority primary endpoint
Akebia Therapeutics · Source ↗
June 2026Topline resultVadadustatVOICE interim analysis met the predefined stopping criteria (non-inferiority and superiority on the primary composite endpoint)

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$37M$16M$160M$14M$2.3M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$49M$14M$157M$8.9M$3.5M operating cash flowreport ↗
2026-Q1$54M$15M$164M$9.1M-$21M operating cash flowreport ↗
2025-Q3$59M$15M$168M—$28M operating cash flowreport ↗
2025-Q2$62M$11M$139M—$22M operating cash flowreport ↗
2025-Q1$57M$9.8M$115M—-$14M operating cash flowreport ↗
2024-Q3$37M$8.5M$36M$20M-$6.7M operating cash flowreport ↗
2024-Q2$44M$7.7M$41M$8.6M-$10M operating cash flowreport ↗
2024-Q1$33M$9.7M$44M$18M-$19M operating cash flowreport ↗
2023-Q3$42M$13M$48M$14M-$7.2M operating cash flowreport ↗
2023-Q2$56M$20M$55M$11M$3.6M operating cash flowreport ↗
2023-Q1$40M$20M$60M$26M-$18M operating cash flowreport ↗
2022-Q3$49M$27M$148M$52M$34M operating cash flowreport ↗
2022-Q2$127M$26M$147M—-$31M operating cash flowreport ↗
2022-Q1$62M$44M$178M$62M-$22M operating cash flowreport ↗
2021-Q3$49M$40M$209M+ $0 short-term inv.$60M-$56M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$236M$62M$187M$1.3M$68M operating cash flowreport ↗

Akebia Therapeutics reported FY2025 revenue of $236.2M, up 47.5% YoY, and R&D spend of $62.36M, up 65.6% YoY. Cash and equivalents stood at $186.54M, with a net loss of $5.34M and quarterly net burn of $5.35M.

The company continued to commercialize Auryxia and Vafseo and advance pipeline candidates AKB-097 and praliciguat. During the year, Akebia entered into an asset purchase agreement with Q32, amended its Cyclerion license arrangement, completed a public stock offering, and added Tranche C under its term loan facility.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$160M$38M$54M$17M-$41M operating cash flowreport ↗
2023-FY$195M$63M$45M$13M-$23M operating cash flowreport ↗
2022-FY$293M$129M$93M$23M-$73M operating cash flowreport ↗
2021-FY$214M$148M$152M+ $0 short-term inv.$71M-$253M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($87K), 16 sales ($963K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-06Butler John P. · director, CEO and PresidentOption exercise350,000$0.63$221KForm 4
2026-08-06Butler John P. · director, CEO and PresidentOption exercise (derivative)350,000——Form 4
2026-06-29Ostrowski Erik · SVP, CFO, CBO & TreasurerOpen-market sale56,019$1.11$62KForm 4
2026-06-17ADAMS ADRIAN · directorAward / grant35,700——Form 4
2026-06-17ZUMWALT LEANNE M · directorAward / grant35,700——Form 4
2026-06-17FRIESON RON · directorAward / grant35,700——Form 4
2026-06-17ROGERS MICHAEL W · directorAward / grant35,700——Form 4
2026-06-17Smith Cynthia · directorAward / grant35,700——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 170 reporting institutions held 101.7M shares ($137.4M, 36.6% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.18,693,296$26.0M
2STATE STREET CORP11,614,006$16.1M
3VANGUARD CAPITAL MANAGEMENT LLC11,166,710$15.5M
4GEODE CAPITAL MANAGEMENT, LLC6,452,252$9.0M
5GOLDMAN SACHS GROUP INC3,602,827$5.0M
6CITIGROUP INC2,854,586$4.0M
7BANK OF AMERICA CORP /DE/2,763,362$3.8M
8Qube Research & Technologies Ltd2,395,215$3.3M
9MILLENNIUM MANAGEMENT LLC2,384,713$3.3M
10VANGUARD PORTFOLIO MANAGEMENT LLC2,215,441$3.1M
11CHARLES SCHWAB INVESTMENT MANAGEMENT INC2,015,577$2.8M
12Nantahala Capital Management, LLC2,000,000$2.8M
13NORTHERN TRUST CORP1,945,586$2.7M
14RENAISSANCE TECHNOLOGIES LLC1,833,128$2.5M
15AQR CAPITAL MANAGEMENT LLC1,792,620$2.5M